...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ESC Heart Failure >Muscle wasting and sarcopenia in heart failure and beyond: update 2017
【24h】

Muscle wasting and sarcopenia in heart failure and beyond: update 2017

机译：心力衰竭及其他方面的肌肉消瘦和肌肉减少症：2017年更新

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Sarcopenia (loss of muscle mass and muscle function) is a strong predictor of frailty, disability and mortality in older persons and may also occur in obese subjects. The prevalence of sarcopenia is increased in patients suffering from chronic heart failure. However, there are currently few therapy options. The main intervention is resistance exercise, either alone or in combination with nutritional support, which seems to enhance the beneficial effects of training. Also, testosterone has been shown to increased muscle power and function; however, a possible limitation is the side effects of testosterone. Other investigational drugs include selective androgen receptor modulators, growth hormone, IGF-1, compounds targeting myostatin signaling, which have their own set of side effects. There are abundant prospective targets for improving muscle function in the elderly with or without chronic heart failure, and the continuing development of new treatment strategies and compounds for sarcopenia and cardiac cachexia makes this field an exciting one.
机译：摘要肌肉减少症（肌肉质量和肌肉功能的丧失）是老年人衰弱，残障和死亡的有力预测指标，肥胖人群中也可能发生。患有慢性心力衰竭的患者的肌肉减少症的患病率增加。但是，目前几乎没有治疗选择。主要干预措施是阻力锻炼，可以单独进行，也可以与营养支持相结合，这似乎可以增强训练的有益效果。同样，睾丸激素已被证明可以增强肌肉力量和功能。然而，可能的限制是睾丸激素的副作用。其他研究药物包括选择性雄激素受体调节剂，生长激素，IGF-1，靶向肌生长抑制素信号传导的化合物，它们具有自己的一系列副作用。有改善或不患有慢性心力衰竭的老年人的肌肉功能的大量预期目标，并且针对肌肉减少症和心脏恶病质的新治疗策略和化合物的不断开发使这一领域成为令人兴奋的领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号